Drug intelligence / Profile preview

2-deoxy-D-ribose

Development stage: Preclinical
Lead developer: Cannenta
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Topical

Overview

2-deoxy-D-ribose (2dDR) is a small molecule sugar-based pro-angiogenic agent being developed by Cannenta for the treatment of chronic and difficult-to-heal wounds, including diabetic foot ulcers. It functions by stimulating the patient's endogenous production of vascular endothelial growth factor (VEGF), which promotes the formation of new blood vessels essential for tissue repair and wound closure. The drug is delivered via a topical hydrogel wound dressing, which is manufactured using electron-beam crosslinked polymer technology in partnership with Nexgel. Cannenta is currently conducting clinical trials for this product in Australia.

Other names: 2-deoxy-D-ribose

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on 2-deoxy-D-ribose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-deoxy-D-ribose.

Explore the full profile